Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Rhea-AI Summary

Beyond Air, Inc. (NASDAQ: XAIR) will report its financial results for the second fiscal quarter ended September 30, 2020, on November 11, 2020, followed by a conference call at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for respiratory conditions and gaseous NO for treating tumors. Its product, LungFit™, can deliver precise NO dosage continuously or at fixed intervals, with ongoing clinical trials targeting severe lung infections, including SARS-CoV-2. For more information, visit www.beyondair.net.

Positive

• Upcoming financial results announcement on November 11, 2020.
• Development of LungFit™ for precise NO delivery in respiratory diseases.
• Ongoing clinical trials for severe lung infections, including COVID-19.

Negative

• None.

Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time

GARDEN CITY, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors and tumor metastases, today announced it will report financial results for its second fiscal quarter ended September 30, 2020 on Wednesday, November 11, 2020. The Company’s management team is scheduled to host a conference call and webcast on at 4:30 pm Eastern Time the same day.

Conference Call & Webcast
Wednesday, November 11 @ 4:30 pm ET
Domestic:	877-407-0784
International:	201-689-8560
Passcode:	13711694
Webcast:	http://public.viavid.com/index.php?id=141855

About Beyond Air, Inc.
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit™ can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit™ for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

CONTACTS:
Steven Lisi, Chief Executive Officer
Beyond Air, Inc.
Slisi@beyondair.net

Maria Yonkoski, Head of Investor Relations
Beyond Air, Inc.
myonkoski@beyondair.net

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

FAQ

When will Beyond Air report its financial results?

Beyond Air will report its financial results for the second fiscal quarter on November 11, 2020.

What is the focus of Beyond Air's research?

Beyond Air focuses on developing inhaled nitric oxide for respiratory conditions and gaseous nitric oxide for treating tumors.

What is LungFit™?

LungFit™ is Beyond Air's innovative system that delivers inhaled nitric oxide for the treatment of pulmonary diseases.

What are the upcoming events for Beyond Air in November 2020?

Beyond Air has a scheduled conference call on November 11, 2020, at 4:30 PM ET to discuss its financial results.